Add Yahoo as a preferred source to see more of our stories on Google. A close up of white woman's wrist, which she's holding as if experiencing pain or joint stiffness. She's sitting on a grey couch ...

Credit: Tonix Pharmaceuticals. Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia. Clinical trials have demonstrated that Tonmya reduces ...

Fibromyalgia patients’ satisfaction with their treatment is predictable through consideration of pre-treatment, patient-specific factors, according to a study in the journal Clinical and Experimental ...

Dear Doctors: I had muscle pain and exhaustion for two years, and no one could figure out what was wrong. A rheumatologist recently diagnosed me with fibromyalgia. I would appreciate any information ...

The Quell ® neuromodulation device (NeuroMetrix) has received the Food and Drug Administration De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia in adults with high pain ...

Many people with fibromyalgia describe the chronic condition as a "bad case of the flu that never goes away," because they have widespread pain, wake up with stiff muscles and experience brain fog, ...

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in more than 15 years. (HealthDay News) — The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine ...

Tonmya is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved Tonmya ™ (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of ...

There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska ...

Tonmya is the first U.S. Food and Drug Administration-approved treatment for fibromyalgia in adults in more than 15 years. ・The drug is a non-opioid therapy for daily bedtime use to manage chronic ...

The main market opportunities in fibromyalgia therapeutics include the significant number of anticipated cases in India by 2029, a limited treatment landscape with few approved drugs and generics ...